NUVL insider exercises options, sells 14,205 shares at $90.04

Q: What did Nuvalent (NUVL)'s CSO report on Form 4?

Exercises of options for 3,668 , 7,495 , and 3,042 shares, and a sale of 14,205 Class A shares.

Q: At what prices were the option exercises and sale reported for NUVL?

Option exercise prices: $18.93 , $27.85 , $72.35 . Sale weighted average price: $90.04 (range $89.84–$90.23 ).

Q: Was the NUVL insider sale under a Rule 10b5-1 plan?

Yes. The transactions were effected under a Rule 10b5-1 plan adopted on November 1, 2024 .

Q: How many NUVL shares does the CSO own after the transactions?

Direct beneficial ownership was 65,963 Class A shares following the reported transactions.

Q: What was the transaction date reported in the NUVL Form 4?

The transactions occurred on 10/15/2025 .

Q: What role does the reporting person hold at Nuvalent (NUVL)?

The reporting person is the Chief Scientific Officer .

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Nuvalent (NUVL) reported insider activity by its Chief Scientific Officer. On 10/15/2025, the officer exercised stock options for 3,668 shares at $18.93, 7,495 shares at $27.85, and 3,042 shares at $72.35, then sold 14,205 Class A shares at a weighted average price of $90.04 (range $89.84–$90.23).

The transactions were made under a Rule 10b5-1 trading plan adopted on November 1, 2024. Following these trades, the officer directly beneficially owned 65,963 Class A shares.

Insider Trade Summary

Net Seller: 14,205 shares ($1,279,018)

Net Sell 7 txns

Insider Pelish Henry E.

Role Chief Scientific Officer

Sold 14,205 shs ($1.28M)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	3,668	$0.00	--
Exercise	Stock Option (Right to Buy)	7,495	$0.00	--
Exercise	Stock Option (Right to Buy)	3,042	$0.00	--
Exercise	Class A Common Stock	3,668	$18.93	$69K
Exercise	Class A Common Stock	7,495	$27.85	$209K
Exercise	Class A Common Stock	3,042	$72.35	$220K
Sale	Class A Common Stock	14,205	$90.04	$1.28M

Holdings After Transaction: Stock Option (Right to Buy) — 10,569 shares (Direct); Class A Common Stock — 69,631 shares (Direct)

Footnotes (1)

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2024. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.84 to $90.23, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price. The shares underlying this option vest as follows: 25% of the shares vested on January 4, 2023, and the remainder have vested or shall vest over the three years thereafter in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date. The shares underlying this option have vested or shall vest over the four years following January 6, 2023 in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date. The shares underlying this option have vested or shall vest over the four years following January 5, 2024 in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.

Form 4 Insider Transactions: What Each Field Means →

10/17/2025 - 04:31 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pelish Henry E.

(Last)

(First)

(Middle)

C/O NUVALENT, INC.

ONE BROADWAY, 14TH FLOOR

(Street)

CAMBRIDGE

02142

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Nuvalent, Inc. [ NUVL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	10/15/2025		M⁽¹⁾		3,668	A	$18.93	69,631	D
Class A Common Stock	10/15/2025		M⁽¹⁾		7,495	A	$27.85	77,126	D
Class A Common Stock	10/15/2025		M⁽¹⁾		3,042	A	$72.35	80,168	D
Class A Common Stock	10/15/2025		S⁽¹⁾		14,205	D	$90.04⁽²⁾	65,963	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$18.93	10/15/2025		M⁽¹⁾			3,668	⁽³⁾	01/04/2032	Class A Common Stock	3,668	$0.00	10,569	D
Stock Option (Right to Buy)	$27.85	10/15/2025		M⁽¹⁾			7,495	⁽⁴⁾	01/06/2033	Class A Common Stock	7,495	$0.00	13,156	D
Stock Option (Right to Buy)	$72.35	10/15/2025		M⁽¹⁾			3,042	⁽⁵⁾	01/05/2034	Class A Common Stock	3,042	$0.00	24,058	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2024.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.84 to $90.23, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price.

3. The shares underlying this option vest as follows: 25% of the shares vested on January 4, 2023, and the remainder have vested or shall vest over the three years thereafter in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.

4. The shares underlying this option have vested or shall vest over the four years following January 6, 2023 in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.

5. The shares underlying this option have vested or shall vest over the four years following January 5, 2024 in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.

	/s/ Nathan N. McConarty, attorney-in-fact	10/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Nuvalent (NUVL)'s CSO report on Form 4?

Exercises of options for 3,668, 7,495, and 3,042 shares, and a sale of 14,205 Class A shares.

At what prices were the option exercises and sale reported for NUVL?

Option exercise prices: $18.93, $27.85, $72.35. Sale weighted average price: $90.04 (range $89.84–$90.23).

Was the NUVL insider sale under a Rule 10b5-1 plan?

Yes. The transactions were effected under a Rule 10b5-1 plan adopted on November 1, 2024.

How many NUVL shares does the CSO own after the transactions?

Direct beneficial ownership was 65,963 Class A shares following the reported transactions.

What was the transaction date reported in the NUVL Form 4?

The transactions occurred on 10/15/2025.

What role does the reporting person hold at Nuvalent (NUVL)?

The reporting person is the Chief Scientific Officer.